Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Apatinib and Chemotherapy in HER-2 Negative MSS GC/GEJ Cancer
NCT05216237Phase 2Unknown
- Start
- Feb 2022
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in gastric cancer (GC), gastroesophageal junction cancer. Status: unknown.
02
Drugs
sintilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05216237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216237.